700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|Tata Memorial Hospital, India|
|Keynote: Clin Exp Pharmacol|
|Background: Angiosarcomasare rare malignant tumors of vascular origin that represent a therapeutic challenge. In recent times,the combination of metronomic therapies and drug repositioning has been proposed as an effective alternative for cancer patients. We tried to explore such therapies in difficult to treat, metastatic/recurrent, angiosarcoma patients. Methods: In vitro experiments with transformed endothelial cells were used to identify synergistic interactions between betablocker propranolol and various chemotherapeutic drugs. This led to exploration of pilot treatment protocol containing oral propranolol along with metronomic therapies. Treatment was delivered for one year followed by oral maintenance till disease progression. Results: Our data shows that all angiosarcoma tumors express ADRB1 and /or ADRB2 adrenergic receptor genes. Propranolol strongly synergized with micro-tubular-targeting agent vinblastine, but only showed additive or slight antagonism with drugs routinely used for the treatment of angiosarcoma viz. doxorubicin and paclitaxel. Based on this data a combination treatment was designed using oral propranolol / weekly injectable metronomic vinblastineand methotrexate, given for up-to 1 year, followed by oral maintenance with propranolol/ etoposide/ cyclophosphamide. This regimen gave us 100% response rate in the 14 patients treated with median PFS of 10.6 months and OS of 17.8 months. The toxicity was acceptable with 3 patients having grade 3 or 4 toxicity (1 Thrombocytopenia, 1 diarrhea, 1 febrile neutropenia). Conclusion: Our data provides strong rationale for the combination of metronomic chemotherapy and propranolol in angiosarcomawhich warrants additional studies. It also illustrates the potentialof metronomics to generate innovative, yet inexpensive, targeted therapies for both high-income and low/middle income countries.|
Shripad Banavali has done his MD in Internal Medicine & Adult Oncology training in India, followed by Board Certification in Pediatrics and Fellowship in Pediatric- Hematology-Oncology in USA. Presently he heads the Department of Medical & Pediatric Oncology at the Tata Memorial Hospital, Mumbai; India. His area of research is Drug Repurposing and development of low-cost, Metronomic Protocols for the treatment of various cancers. He has more than 170 publications. He is recipient of 5 Orations and has received the International “Barton Kamen Prize” in recognition of Research on Metronomics in Childhood cancers.
Email: [email protected]
|PDF | HTML|